INSMED INC Increase (Decrease) in Accounts Payable and Accrued Liabilities
INSMED INC (INSM) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $34.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $68.82M, a 168.22% increase year-over-year.
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$33.88M.
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $90.35M, a 119.66% increase year-over-year.
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $45.56M, a 6184.00% increase year-over-year.
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $100.07M, a 124.42% increase from fiscal 2024.
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $44.59M, a 194.24% increase from fiscal 2023.
- INSMED INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $15.15M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $34.95M 10-Q · filed 2026-08-06 | $125.29M derived: sum of 3 quarters · filed 2026-08-06 | $170.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$33.88M 10-Q · filed 2026-05-07 | $56.47M derived: sum of 2 quarters · filed 2026-05-07 | $102.03M derived: sum of 3 quarters · filed 2026-05-07 | $127.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $90.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $135.91M derived: sum of 2 quarters · filed 2026-02-19 | $161.56M derived: sum of 3 quarters · filed 2026-08-06 | $100.07M 10-K · filed 2026-02-19 |
| 2025-09-30 | $45.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $71.22M derived: sum of 2 quarters · filed 2026-08-06 | $9.73M 10-Q · filed 2025-10-30 | $50.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$35.83M 10-Q · filed 2026-08-06 | $5.30M derived: sum of 3 quarters · filed 2026-08-06 | $6.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$61.49M 10-Q · filed 2026-05-07 | -$20.36M derived: sum of 2 quarters · filed 2026-05-07 | -$19.64M derived: sum of 3 quarters · filed 2026-05-07 | $15.45M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $41.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $41.85M derived: sum of 2 quarters · filed 2026-02-19 | $76.94M derived: sum of 3 quarters · filed 2026-02-19 | $44.59M 10-K · filed 2026-02-19 |
| 2024-09-30 | $725.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $35.81M derived: sum of 2 quarters · filed 2025-10-30 | $3.46M 10-Q · filed 2025-10-30 | $25.17M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $35.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.74M 10-Q · filed 2025-08-07 | $24.45M derived: sum of 3 quarters · filed 2026-02-19 | $17.67M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$32.34M 10-Q · filed 2025-05-08 | -$10.64M derived: sum of 2 quarters · filed 2026-02-19 | -$17.41M derived: sum of 3 quarters · filed 2026-02-19 | -$8.35M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $21.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $14.93M derived: sum of 2 quarters · filed 2026-02-19 | $24.00M derived: sum of 3 quarters · filed 2026-02-19 | $15.15M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$6.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.29M derived: sum of 2 quarters · filed 2024-10-31 | -$6.55M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $9.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $224.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$8.84M 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $18.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $1.77M derived: sum of 2 quarters · filed 2023-10-26 | $15.14M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | -$16.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$3.56M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $13.36M 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | -$4.06M 10-Q · filed 2022-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |